Pre-Made Dezamizumab biosimilar, Whole mAb, Anti-APCS Antibody: Anti-HEL-S-92n/PTX2/SAP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pre-made Dezamizumab benchmark antibody ( Whole mAb, anti-APCS therapeutic antibody, Anti-HEL-S-92n/PTX2/SAP Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-144
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Products Name (INN Index) | Pre-Made Dezamizumab biosimilar, Whole mAb, Anti-APCS Antibody: Anti-HEL-S-92n/PTX2/SAP therapeutic antibody |
---|---|
INN Name | Dezamizumab |
Target | APCS |
Format | Whole mAb |
Derivation | Humanized |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-II |
Est. Status | Discontinued |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2016 |
Year Recommended | 2017 |
Companies | Pentraxin Therapeutics,GlaxoSmithKline |
Conditions Approved | NA |
Conditions Active | NA |
Conditions Discontinued | Amyloidosis |
Development Tech | NA |
Previous Name | NA |
Gm Offical Target Name | APCS |
Package |
Genemeidi Omicron Variant Products
test
Previous slide
Next slide